ArticleBritish journal of cancer2026
ULK1 promotes oxaliplatin resistance of colon cancer via phosphorylation of Bax S184.
Article in British journal of cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundOxaliplatin resistance continues to undermine therapeutic outcomes in colon cancer (CC). Recent investigations point to unc-51 like kinase 1 (ULK1)-mediated disruption of apoptotic pathways as a potential driver of chemoresistance, though the exact mechanisms remain incompletely characterized.
methodsUsing established CC cell lines, we developed oxaliplatin-resistant models through stepwise dose escalation. ULK1 expression was modulated through targeted siRNA knockdown and stable overexpression. Protein interactions were examined via co-immunoprecipitation coupled with mass spectrometry, supplemented by kinase activity assays. Functional impact was assessed through proliferation kinetics, apoptosis profiling, and tumor xenograft studies. Clinical correlations were derived from TCGA analysis and immunohistochemical evaluation of patient tumor specimens.
resultsULK1 overexpression consistently correlated with oxaliplatin resistance and adverse clinical parameters. At the molecular level, ULK1 catalyzed Bcl-2 associated X protein (Bax) phosphorylation at Ser184, creating a recognition motif for Parkin-mediated ubiquitination and proteasomal targeting. Disruption of this axis through ULK1 inhibition restored Bax protein levels, enhanced apoptotic response, and reversed oxaliplatin resistance in both cellular and animal models.
conclusionThese findings identify ULK1-dependent phosphorylation as a novel regulatory mechanism governing Bax stability in CC. The study provides preclinical rationale for targeting the ULK1-Bax interface to overcome oxaliplatin resistance, while highlighting the need for further investigation into optimal therapeutic strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.